Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Weiguo Qing"'
Autor:
Steven W. Elmore, Saul H. Rosenberg, Stephen W. Fesik, Haichao Zhang, Robert Warner, Baole Wang, Stephen K. Tahir, Jason Stavropoulos, Wang Shen, Weiguo Qing, Tilman Oltersdorf, Jacqueline M. O'Connor, Paul Nimmer, ShiChung Ng, Hugh Nellans, William McClellan, Kennan Marsh, Mary K. Joseph, Ken Jarvis, David J. Frost, Thomas Deckwirth, Milan Bruncko, Tony Borre, Barbara A. Belli, Joy Bauch, Anatol Oleksijew, Alex R. Shoemaker
Supplementary Table 1 from A Small-Molecule Inhibitor of Bcl-XL Potentiates the Activity of Cytotoxic Drugs In vitro and In vivo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ffdcab05705218f3464129646e1c086
https://doi.org/10.1158/0008-5472.22364780
https://doi.org/10.1158/0008-5472.22364780
Autor:
Steven W. Elmore, Saul H. Rosenberg, Stephen W. Fesik, Haichao Zhang, Robert Warner, Baole Wang, Stephen K. Tahir, Jason Stavropoulos, Wang Shen, Weiguo Qing, Tilman Oltersdorf, Jacqueline M. O'Connor, Paul Nimmer, ShiChung Ng, Hugh Nellans, William McClellan, Kennan Marsh, Mary K. Joseph, Ken Jarvis, David J. Frost, Thomas Deckwirth, Milan Bruncko, Tony Borre, Barbara A. Belli, Joy Bauch, Anatol Oleksijew, Alex R. Shoemaker
Inhibition of the prosurvival members of the Bcl-2 family of proteins represents an attractive strategy for the treatment of cancer. We have previously reported the activity of ABT-737, a potent inhibitor of Bcl-2, Bcl-XL, and Bcl-w, which exhibits m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b32fe1ff45a9b469ce5c540c767346d
https://doi.org/10.1158/0008-5472.c.6494357.v1
https://doi.org/10.1158/0008-5472.c.6494357.v1
Autor:
Linfang Wang, Junqing Liang, Zhihu Gao, Jia Hu, Weigang He, Xianwen Yang, Fangfang Mao, Wei Zhang, Ying Yu, Qihang Zhang, Na Yang, Chun Zhang, Jian Wang, Yu Cai, Xiong Li, Weiguo Qing, Guangxiu Dai, Yongxin Ren, Michael Shi, Weiguo Su
Publikováno v:
Cancer Research. 83:4020-4020
Introduction: Bruton’s tyrosine kinase (BTK), a member of the Tec family, plays a crucial role in signaling through B-cell receptor (BCR). BTK inhibition blocks BCR signals and prevents B-cell activation and growth. First-generation BTK inhibitors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a09a9b8ebf5c0aed87be4b4d954003e9
https://doi.org/10.1158/1538-7445.am2023-4020
https://doi.org/10.1158/1538-7445.am2023-4020
Autor:
Jia Hu, Jianhan Wang, Xiaoming Dai, Jianlin He, Junqing Liang, Ying Yu, Juntao Yu, Na Yang, Linfang Wang, Yu Cai, Xiong Li, Weiguo Qing, Yongxin Ren, Weiguo Su
Publikováno v:
Cancer Research. 82:5454-5454
Background: The delta isoform of PI3K (PI3Kδ) plays an important role in B-cell development and function by mediating the signaling of key receptors on B cells. Aberrant activation of PI3Kδ signaling pathway promotes the survival and proliferation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::50ca9a278cf06a22e1c24584d9781a71
https://doi.org/10.1158/1538-7445.am2022-5454
https://doi.org/10.1158/1538-7445.am2022-5454
Autor:
Guanglin Wang, Weiguo Su, Shiming Fan, Yongxin Ren, Meijing Yu, Yang Sai, Li Zhang, Jian Wang, Hongcan Ren, Yi Gu, Weiguo Qing
Publikováno v:
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 136
Savolitinib is a novel small-molecule selective cMet inhibitor. This work characterized its pharmacokinetics in preclinical phase, established the preclinical relationships between PK, cMet modulation and anti-tumor efficacy. In vitro and in vivo ani
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48a60a99908eddea26a03b4116ed754d
https://pubmed.ncbi.nlm.nih.gov/31132401
https://pubmed.ncbi.nlm.nih.gov/31132401
Autor:
Huaqing Cai, Zheng Yang, Minhua Hong, Jinghong Zhou, Fang Yin, Liang Ni, Junqing Liang, Zheng Zhang, Weihan Zhang, Meifang Zhang, Yi Gu, Yang Sai, Qiaoling Sun, Haibin Yang, Junen Sun, Feng Zhou, Mingchuan Guo, Yongxin Ren, Weiguo Su, Yumin Cui, Wei Zhang, Jingwen Long, Weiguo Qing
Publikováno v:
Cancer Biology & Therapy. 15:1635-1645
VEGF/VEGFR signal axis has been proven to be an important target for development of novel cancer therapies. One challenging aspect in small molecular VEGFR inhibitors is to achieve sustained target inhibition at tolerable doses previously seen only w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65901e3a00fcf41e5d692cceb8b6409b
https://doi.org/10.4161/15384047.2014.964087
https://doi.org/10.4161/15384047.2014.964087
Autor:
Longxian Jiao, Hong Jia, Weiguo Su, Shiming Fan, Weiguo Qing, Jing Wang, Yi Gu, Yumin Cui, Guangxiu Dai, Jinghong Zhou, Zhulin Zhang, Yang Sai, Jianyang Weng, Qing Wang, Feng Zhou, Yongxin Ren
Publikováno v:
Journal of Medicinal Chemistry. 57:7577-7589
HGF/c-Met signaling has been implicated in human cancers. Herein we describe the invention of a series of novel triazolopyrazine c-Met inhibitors. The structure-activity relationship of these compounds was investigated, leading to the identification
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bbff1b6057dd3d1e8ae9702139365d6c
https://doi.org/10.1021/jm500510f
https://doi.org/10.1021/jm500510f
Autor:
Linfang Wang, Jianming Zheng, Yunxin Chen, Dongxia Shi, Renxiang Tang, Weihan Zhang, Weiguo Su, Weiguo Qing, Haibin Yang, Min Cheng, Jun Ni, Shiming Fan, Fang Yin, Longxian Jiao, Wei Zhang, Huaqing Cai, Feng Zhou, Yongxin Ren, Ying Yu
Publikováno v:
Oncotarget
// Yongxin Ren 1, * , Jianming Zheng 2, * , Shiming Fan 1, * , Linfang Wang 1 , Min Cheng 1 , Dongxia Shi 1 , Wei Zhang 1 , Renxiang Tang 1 , Ying Yu 1 , Longxian Jiao 1 , Jun Ni 1 , Haibin Yang 3 , Huaqing Cai 3 , Fang Yin 1 , Yunxin Chen 1 , Feng Z
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a0ecc8c63af72cf733c2b27cff5ee06
https://pubmed.ncbi.nlm.nih.gov/28881608
https://pubmed.ncbi.nlm.nih.gov/28881608
Autor:
Michael Zinda, Garry Beran, Lillian Castriotta, Yongxin Ren, Feng Zhou, Alwin Schuller, Brendon Ladd, Aleksandra Markovets, Corinne Reimer, Celina M. D'Cruz, Edwin Clark, Weiguo Qing, Weiguo Su, Evan Barry, Ryan E. Henry, Ammar Adam
Publikováno v:
Oncotarget
// Ryan E. Henry 1,* , Evan R. Barry 1,* , Lillian Castriotta 1 , Brendon Ladd 1 , Aleksandra Markovets 1 , Garry Beran 2 , Yongxin Ren 3 , Feng Zhou 3 , Ammar Adam 1 , Michael Zinda 1 , Corinne Reimer 1 , Weiguo Qing 3 , Weiguo Su 3 , Edwin Clark 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f9fd1fedf65397e6428d6074953fd44
https://pubmed.ncbi.nlm.nih.gov/27472392
https://pubmed.ncbi.nlm.nih.gov/27472392
Autor:
Zoran Filipovic, Weiguo Qing, Binh Thanh Vu, Ola Myklebost, Packman Kathryn E, Brian Higgins, Lyubomir T. Vassilev, Kenneth Kolinsky, David C. Heimbrook, Xiaolan Zhao, Holly Hilton, Jim Rosinski, Christian Tovar
Publikováno v:
Proceedings of the National Academy of Sciences. 103:1888-1893
The p53 tumor suppressor retains its wild-type conformation and transcriptional activity in half of all human tumors, and its activation may offer a therapeutic benefit. However, p53 function could be compromised by defective signaling in the p53 pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f4badbc62ab99d10d038b2ce376a88b
https://doi.org/10.1073/pnas.0507493103
https://doi.org/10.1073/pnas.0507493103